Dr. Danko Martincic, MD
Hematology & Oncology (Hematology & Oncology Physician)
1641 E Polston Ave Ste 102
Post Falls, ID 83854
Who else practices at this address →
Kootenai County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 474
Licensed in Washington since 2006, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
ID license MC-0445 · WA license MD00046391 (first issued 2006; active) -
Hematology (Internal Medicine) Physician
ID license MC-0445 -
Medical Oncology Physician
ID license MC-0445
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Kootenai Health Coeur D'alene, ID
- Northwest Specialty Hospital Post Falls, ID
- Bonner General Hospital Sandpoint, ID
- Benewah Community Hospital Saint Maries, ID
- Shoshone Medical Center Kellogg, ID
Medical groups
- Beacon Cancer Care PLLC (18 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 474
- Services billed
- 315,005
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, nivolumab, 1 mg | 46,090 | 24 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 22,950 | 20 |
| Injection, pembrolizumab, 1 mg | 20,200 | 21 |
| Injection, paclitaxel, 1 mg | 6,888 | 16 |
| Injection, dexamethasone sodium phosphate, 1 mg | 6,862 | 88 |
| Injection, fosaprepitant, 1 mg | 5,400 | 12 |
| Injection, denosumab, 1 mg | 5,340 | 20 |
| Injection, ipilimumab, 1 mg | 3,160 | 11 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,910 | 12 |
| Injection, palonosetron hcl, 25 mcg | 2,780 | 50 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Post Falls, ID | 106 |
| Letrozole Other prescribers in Post Falls, ID | 42 |
| Levothyroxine Sodium Other prescribers in Post Falls, ID | 40 |
| Jakafi (ruxolitinib phosphate) | 37 |
| Revlimid (lenalidomide) | 37 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Post Falls, ID | 36 |
| Gabapentin Other prescribers in Post Falls, ID | 30 |
| Acyclovir Other prescribers in Post Falls, ID | 27 |
| Abiraterone Acetate | 26 |
| Ondansetron Odt (ondansetron) Other prescribers in Post Falls, ID | 26 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 36 companies reported 226 payments worth $189,966 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $60,430 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $52,956 |
| Pfizer Inc. | $29,210 |
| Merck Sharp & Dohme LLC | $14,636 |
| Regeneron Healthcare Solutions, Inc. | $14,481 |
| Daiichi Sankyo Inc. | $13,212 |
| Astellas Pharma US Inc | $1,925 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $916 |
| Compensation for services other than consulting (speaking, faculty) | $122,880 |
|---|---|
| Consulting Fee | $45,820 |
| Travel and Lodging | $15,896 |
| Food and Beverage | $5,271 |
| Education | $99.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $7,280 |
| E.r. Squibb & Sons, L.l.c. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $7,280 |
| E.r. Squibb & Sons, L.l.c. May 30, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $7,280 |
| AstraZeneca Pharmaceuticals LP May 20, 2025 | Compensation for services other than consulting (speaking, faculty) ENHERTU · Oncology Company’s descriptionSpeaker Fee | $6,030 |
| AstraZeneca Pharmaceuticals LP Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $6,030 |
| Pfizer Inc. May 6, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $5,820 |
| Merck Sharp & Dohme LLC Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $5,760 |
| Merck Sharp & Dohme LLC Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $5,760 |
| E.r. Squibb & Sons, L.l.c. Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $5,460 |
| Pfizer Inc. Apr 2, 2025 | Consulting Fee PADCEV · ONCOLOGY | $5,400 |
All 85 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Nov 24, 2025 | Consulting Fee Padcev · Oncology | $300 |
| Pfizer Inc. Nov 17, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $4,000 |
| Merck Sharp & Dohme LLC Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $5,760 |
| Pfizer Inc. Nov 14, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $1,300 |
| Pfizer Inc. Nov 14, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $325 |
| Merck Sharp & Dohme LLC Nov 14, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Lewiston, ID | $150 |
| Merck Sharp & Dohme LLC Nov 13, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Moscow, ID | $150 |
| Regeneron Healthcare Solutions, Inc. Nov 12, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $945 |
| Merck Sharp & Dohme LLC Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $5,760 |
| Merck Sharp & Dohme LLC Nov 4, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Lewiston, ID · in-kind | $1,008 |
| Merck Sharp & Dohme LLC Oct 30, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Moscow, ID · in-kind | $1,464 |
| Regeneron Healthcare Solutions, Inc. Oct 24, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $923 |
| Astellas Pharma US Inc Sep 29, 2025 | Consulting Fee Padcev · Oncology | $750 |
| E.r. Squibb & Sons, L.l.c. Sep 17, 2025 | Consulting Fee | $455 |
| Daiichi Sankyo Inc. Aug 22, 2025 | Consulting Fee Enhertu · ONCOLOGY | $670 |
| AstraZeneca Pharmaceuticals LP Aug 19, 2025 | Consulting Fee | $2,680 |
| E.r. Squibb & Sons, L.l.c. Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $3,640 |
| AstraZeneca Pharmaceuticals LP Jul 31, 2025 | Travel and Lodging ENHERTU · Oncology · travel to Bozeman, MT · in-kind Company’s descriptionSpeaker Expenses | $35.00 |
| E.r. Squibb & Sons, L.l.c. Jul 21, 2025 | Consulting Fee | $1,820 |
| AstraZeneca Pharmaceuticals LP Jul 16, 2025 | Consulting Fee | $670 |
| E.r. Squibb & Sons, L.l.c. Jul 15, 2025 | Consulting Fee | $455 |
| Astellas Pharma US Inc Jul 5, 2025 | Compensation for services other than consulting (speaking, faculty) Padcev · Oncology | $856 |
| E.r. Squibb & Sons, L.l.c. Jun 16, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $5,460 |
| Daiichi Sankyo Inc. Jun 10, 2025 | Compensation for services other than consulting (speaking, faculty) Enhertu · ONCOLOGY | $4,020 |
| E.r. Squibb & Sons, L.l.c. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $7,280 |
| AstraZeneca Pharmaceuticals LP Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) ENHERTU · Oncology Company’s descriptionSpeaker Fee | $5,360 |
| AstraZeneca Pharmaceuticals LP Jun 3, 2025 | Travel and Lodging ENHERTU · Oncology · travel to Bend, OR · in-kind Company’s descriptionSpeaker Expenses | $1,001 |
| AstraZeneca Pharmaceuticals LP Jun 3, 2025 | Travel and Lodging ENHERTU · Oncology · travel to Bend, OR · in-kind Company’s descriptionSpeaker Expenses | $330 |
| E.r. Squibb & Sons, L.l.c. May 30, 2025 | Compensation for services other than consulting (speaking, faculty) OPDIVO · Oncology | $7,280 |
| AstraZeneca Pharmaceuticals LP May 30, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $5,360 |
| AstraZeneca Pharmaceuticals LP May 28, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $4,020 |
| E.r. Squibb & Sons, L.l.c. May 28, 2025 | Travel and Lodging OPDIVO · Oncology · travel to Wenatchee, WA | $1,431 |
| Seagen Inc. May 28, 2025 | Education in-kind | $99.00 |
| AstraZeneca Pharmaceuticals LP May 20, 2025 | Compensation for services other than consulting (speaking, faculty) ENHERTU · Oncology Company’s descriptionSpeaker Fee | $6,030 |
| Boehringer Ingelheim Pharmaceuticals, Inc. May 20, 2025 | Consulting Fee | $870 |
| E.r. Squibb & Sons, L.l.c. May 20, 2025 | Travel and Lodging REBLOZYL · Hematology · travel to Seattle, WA | $587 |
| E.r. Squibb & Sons, L.l.c. May 20, 2025 | Consulting Fee | $455 |
| E.r. Squibb & Sons, L.l.c. May 20, 2025 | Travel and Lodging REBLOZYL · Hematology · travel to Seattle, WA | $392 |
| E.r. Squibb & Sons, L.l.c. May 15, 2025 | Consulting Fee | $1,820 |
| E.r. Squibb & Sons, L.l.c. May 15, 2025 | Consulting Fee | $1,820 |
| AstraZeneca Pharmaceuticals LP May 15, 2025 | Travel and Lodging ENHERTU · Oncology · travel to Medford, OR · in-kind Company’s descriptionSpeaker Expenses | $576 |
| AstraZeneca Pharmaceuticals LP May 15, 2025 | Travel and Lodging ENHERTU · Oncology · travel to Medford, OR · in-kind Company’s descriptionSpeaker Expenses | $189 |
| AstraZeneca Pharmaceuticals LP May 13, 2025 | Consulting Fee IMFINZI · Oncology | $1,675 |
| E.r. Squibb & Sons, L.l.c. May 8, 2025 | Travel and Lodging OPDIVO · Oncology · travel to Tacoma, WA | $633 |
| E.r. Squibb & Sons, L.l.c. May 8, 2025 | Travel and Lodging OPDIVO · Oncology · travel to Tacoma, WA | $422 |
| AstraZeneca Pharmaceuticals LP May 7, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $3,350 |
| Pfizer Inc. May 6, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $5,820 |
| E.r. Squibb & Sons, L.l.c. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $3,185 |
| Pfizer Inc. Apr 26, 2025 | Travel and Lodging ADCETRIS · ONCOLOGY · travel to Dallas, TX · in-kind | $679 |
| Pfizer Inc. Apr 26, 2025 | Travel and Lodging ADCETRIS · ONCOLOGY · travel to Dallas, TX · in-kind | $327 |
| Regeneron Healthcare Solutions, Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,272 |
| Regeneron Healthcare Solutions, Inc. Apr 25, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TACOMA, WA · in-kind | $666 |
| AstraZeneca Pharmaceuticals LP Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $6,030 |
| AstraZeneca Pharmaceuticals LP Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $300 |
| AstraZeneca Pharmaceuticals LP Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) ENHERTU · Oncology Company’s descriptionSpeaker Fee | $5,360 |
| Regeneron Healthcare Solutions, Inc. Apr 8, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to WENATCHEE, WA · in-kind | $237 |
| AstraZeneca Pharmaceuticals LP Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $3,350 |
| AstraZeneca Pharmaceuticals LP Apr 3, 2025 | Travel and Lodging ENHERTU · Oncology · travel to Portland, OR · in-kind Company’s descriptionSpeaker Expenses | $701 |
| AstraZeneca Pharmaceuticals LP Apr 3, 2025 | Travel and Lodging ENHERTU · Oncology · travel to Portland, OR · in-kind Company’s descriptionSpeaker Expenses | $363 |
| Pfizer Inc. Apr 2, 2025 | Consulting Fee PADCEV · ONCOLOGY | $5,400 |
| Daiichi Sankyo Inc. Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) Enhertu · ONCOLOGY | $5,360 |
| Regeneron Healthcare Solutions, Inc. Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $5,272 |
| Pfizer Inc. Mar 31, 2025 | Travel and Lodging PADCEV · ONCOLOGY · travel to San Diego, CA · in-kind | $540 |
| Pfizer Inc. Mar 31, 2025 | Travel and Lodging PADCEV · ONCOLOGY · travel to San Diego, CA · in-kind | $528 |
| Pfizer Inc. Mar 31, 2025 | Travel and Lodging PADCEV · ONCOLOGY · travel to San Diego, CA · in-kind | $393 |
| Regeneron Healthcare Solutions, Inc. Mar 31, 2025 | Travel and Lodging LIBTAYO · ONCOLOGY · travel to TACOMA, WA · in-kind | $217 |
| E.r. Squibb & Sons, L.l.c. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $7,280 |
| AstraZeneca Pharmaceuticals LP Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) ENHERTU · Oncology Company’s descriptionSpeaker Fee | $5,360 |
| Pfizer Inc. Mar 13, 2025 | Consulting Fee ADCETRIS · ONCOLOGY | $5,125 |
| AstraZeneca Pharmaceuticals LP Mar 5, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $5,360 |
| E.r. Squibb & Sons, L.l.c. Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) REBLOZYL · Hematology | $3,640 |
| E.r. Squibb & Sons, L.l.c. Mar 4, 2025 | Travel and Lodging REBLOZYL · Hematology · travel to Everett, WA | $438 |
| E.r. Squibb & Sons, L.l.c. Mar 4, 2025 | Travel and Lodging REBLOZYL · Hematology · travel to Everett, WA | $342 |
| E.r. Squibb & Sons, L.l.c. Feb 27, 2025 | Consulting Fee | $1,820 |
| AstraZeneca Pharmaceuticals LP Feb 26, 2025 | Travel and Lodging travel to Tigard, OR · in-kind Company’s descriptionSpeaker Expenses | $813 |
| AstraZeneca Pharmaceuticals LP Feb 26, 2025 | Travel and Lodging travel to Tigard, OR · in-kind Company’s descriptionSpeaker Expenses | $31.08 |
| E.r. Squibb & Sons, L.l.c. Feb 25, 2025 | Consulting Fee | $1,820 |
| Daiichi Sankyo Inc. Feb 20, 2025 | Consulting Fee Enhertu · ONCOLOGY | $1,665 |
| Daiichi Sankyo Inc. Feb 20, 2025 | Consulting Fee Enhertu · ONCOLOGY | $670 |
| Daiichi Sankyo Inc. Feb 20, 2025 | Consulting Fee Enhertu · ONCOLOGY | $555 |
| Pfizer Inc. Jan 29, 2025 | Consulting Fee PADCEV · ONCOLOGY | $2,880 |
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Compensation for services other than consulting (speaking, faculty) IMFINZI · Oncology Company’s descriptionSpeaker Fee | $300 |
| Pfizer Inc. Jan 18, 2025 | Travel and Lodging ADCETRIS · ONCOLOGY · travel to Portland, OR · in-kind | $707 |
| Pfizer Inc. Jan 18, 2025 | Travel and Lodging ADCETRIS · ONCOLOGY · travel to Portland, OR · in-kind | $547 |
| Regeneron Healthcare Solutions, Inc. Jan 9, 2025 | Compensation for services other than consulting (speaking, faculty) LIBTAYO · ONCOLOGY | $768 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 8 companies. The companies reported $449,763 in research payments for these studies, mostly to the institutions running them.
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT06191744 - A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for…
AstraZeneca UK Limited - A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06246916 - A Phase Ib/II open-label, multi-center study of the safety and efficacy of IMCgp100 in combination with MEDI4736 or tremelimumab or the combination of MEDI4736 and tremelimumab compared to IMCgp100 alone in patients w…
AstraZeneca UK Limited - A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stag…
Merck Sharp & Dohme LLC - Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors
Deciphera Pharmaceuticals Inc. · Terminated · NCT04892017 - A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Nec…
Merck Sharp & Dohme LLC - A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-7902 in combination with pembrolizumab MK-3475 versus standard of care chemotherapy and lenvatinib …
Merck Sharp & Dohme LLC - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular…
AbbVie Inc. - Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.